OCEAN(a)-DOSE -TIMI 67

A study to evaluate the efficacy, safety, and tolerability of Olpasiran (AMG890, a small interfering RNA) in subjects with elevated lipoprotein(a).

AMG 890 Ph2 study schema-10-6-22

MAIN RESULTS:
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Ocean(a)

PUBLICATIONS

Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial. Am Heart J. 2022 May 16;251:61-69.

OCEAN(a)-DOSE on ClinicalTrials.gov

Contact Us about OCEAN(a)-DOSE

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close